Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report

作者：Zhang, Cuifen; Wang, Ke; Zhang, Hong; Liu, Jingjing; Zheng, Chuangjie; Tao, Jiahao; Lin, Lizhu; Zhai, Linzhu^*

来源：Clinical, Cosmetic and Investigational Dermatology, 2023, 16: 2429-2432.

DOI：10.2147/CCID.S415119

• onychopathy
• durvalumab
• ES-SCLC
• immune checkpoint inhibitors
• immune-related adverse events

Patients treated with immune checkpoint inhibitors (ICIS) are prone to immune related adverse events (irAEs), making it important to pay attention to these adverse events. Herein, we report a case of onychopathy after treatment of extensive small cell lung cancer (ES-SCLC) with durvalumab; this is the first report of onychopathy caused by durvalumab in a patient with lung cancer. The change in the patient's nails mainly manifested in the form of pigmentation and the thickening of the nails. Antifungal ointment was ineffective, and these changes were unrelated to malnutrition or any other factors. In addition, this case shows that onychopathy may occur within 2 years after treatment, indicating that these patients need long-term follow-up.

• 单位
  广州中医药大学; 1